Truly Labs

Executive Summary

Truly Labs (operating as Truly Translational) is a Stockholm-based preclinical and early clinical drug development consultancy founded in 2020. The company provides strategic advisory and hands-on laboratory services, including in vitro and in vivo studies, to help clients transition from project concepts to efficient experimental plans and conclusive clinical trials. With expertise spanning small molecules, RNAs, proteins, and cells, Truly Labs positions itself as a versatile partner for biotech and pharmaceutical clients across multiple drug modalities. Its service model addresses a critical industry need for specialized translational support, particularly for emerging companies lacking in-house capabilities. As a private, pre-clinical stage firm with no disclosed funding rounds, Truly Labs operates with a lean, fee-for-service business model that mitigates typical drug development risks. The company's growth trajectory likely hinges on expanding its client base, forging strategic partnerships, and potentially developing proprietary platforms. While detailed financials and near-term milestones are undisclosed, the Swedish life sciences ecosystem and increasing demand for outsourced R&D support provide favorable tailwinds. Key catalysts include onboarding anchor clients, launching new service offerings in high-demand areas (e.g., gene therapy or RNA therapeutics), and securing collaborations with academic institutions or larger pharma partners.

Upcoming Catalysts (preview)

• Q3 2026Announcement of Major Client Contract or Multi-Project Agreement70% success
• Q4 2026Launch of Specialized Service Line in Gene Therapy or RNA Therapeutics50% success
• H1 2027Completion of Strategic Partnership with a Swedish Academic Research Hub40% success